KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average): 2011-2025

Historic Shares Outstanding (Diluted Average) for Supernus Pharmaceuticals (SUPN) over the last 10 years, with Sep 2025 value amounting to $56.6 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 0.96% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 0.96%. This contributed to the annual value of $56.0 million for FY2024, which is 0.81% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $56.6 million, which was down 0.24% from $56.7 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $62.5 million during Q1 2023, with a 5-year trough of $54.2 million in Q1 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $56.8 million, with its median value being $56.0 million (2024).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) increased by 13.47% in 2022 and then declined by 10.93% in 2024.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $54.4 million in 2021, then climbed by 13.47% to $61.7 million in 2022, then declined by 10.01% to $55.5 million in 2023, then increased by 0.81% to $56.0 million in 2024, then grew by 0.96% to $56.6 million in 2025.
  • Its last three reported values are $56.6 million in Q3 2025, $56.7 million for Q2 2025, and $55.9 million during Q1 2025.